Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC study

Drug and Alcohol Dependence

Volumn 107, Issue 2-3, 2010, Pages 244-249

  Grebely, J ^a   Petoumenos, K ^a   Matthews, G V ^a,b   Haber, P ^c,d   Marks, P ^a   Lloyd, A R ^e   Kaldor, J M ^a   Dore, G J ^a,b   Hellard, M ^f,g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f BURNET INSTITUTE   (Australia)

^g ALFRED HOSPITAL   (Australia)

Author keywords

Acute; Hepatitis C virus; Injection drug users; Pegylated interferon; Treatment

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG DEPENDENCE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PREDICTION; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; AUSTRALIA; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; METHADONE; NARCOTICS; PATIENT COMPLIANCE; POLYETHYLENE GLYCOLS; RNA, VIRAL; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 77649182326     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.09.015     Document Type: Article

References (38)

1. Adeyemi O.M., Jensen D., Attar B., Ghaoui R., Gallagher M., Wolen D., Cotler S.J. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care and STDs 2004, 18:239-245.
2. Cox A.L., Netski D.M., Mosbruger T., Sherman S.G., Strathdee S., Ompad D., Vlahov D., Chien D., Shyamala V., Ray S.C., Thomas D.L. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis. 2005, 40:951-958.
3. Darke S., Hall W., Wodak A., Heather N., Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br. J. Addict. 1992, 87:733-742.
4. De Rosa F.G., Bargiacchi O., Audagnotto S., Garazzino S., Cariti G., Veronese L., Raiteri R., Calleri G., Di Perri G. The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b. Antivir. Ther. 2006, 11:165-171.
5. Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin. Infect. Dis. 2005, 40(Suppl 5):S313-S320.
6. Dore G.J., Hellard M., Matthews G.V., Grebely J., Haber P.S., Petoumenos K., Yeung B., Marks P., van Beek I., McCaughan G., White P., Ffrench R., Rawlinson W., Lloyd A.R., Kaldor J.M. Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection. Gastroenterology 2009, ATAHC Study Group, [Epub ahead of print].
7. Edlin B.R., Kresina T.F., Raymond D.B., Carden M.R., Gourevitch M.N., Rich J.D., Cheever L.W., Cargill V.A. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin. Infect. Dis. 2005, 40(Suppl 5):S276-S285.
8. Falck-Ytter Y., Kale H., Mullen K.D., Sarbah S.A., Sorescu L., McCullough A.J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann. Intern. Med. 2002, 136:288-292.
9. Fishbein D.A., Lo Y., Reinus J.F., Gourevitch M.N., Klein R.S. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J. Acquir Immune Defic. Syndr. 2004, 37:1367-1375.
10. Fleming C.A., Craven D.E., Thornton D., Tumilty S., Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin. Infect. Dis. 2003, 36:97-100.
11. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M., Ulsenheimer A., Schraut W.W., Schirren C.A., Waechtler M., Backmund M., Pape G.R. Acute Hepatitis C; high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 80-88.
12. Glynn S.A., Wright D.J., Kleinman S.H., Hirschkorn D., Tu Y., Heldebrant C., Smith R., Giachetti C., Gallarda J., Busch M.P. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005, 45:994-1002.
13. Grebely J., Genoway K.A., Raffa J.D., Dhadwal G., Rajan T., Showler G., Kalousek K., Duncan F., Tyndall M.W., Fraser C., Conway B., Fischer B. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol. Depend. 2008, 93:141-147.
14. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., Tyndall M.W. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J. Viral Hepat. 2009, 16:352-358.
15. Groom H., Dieperink E., Nelson D.B., Garrard J., Johnson J.R., Ewing S.L., Stockley H., Durfee J., Jonk Y., Willenbring M.L., Ho S.B. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J. Clin. Gastroenterol. 2008, 42:97-106.
16. Hall C.S., Charlebois E.D., Hahn J.A., Moss A.R., Bangsberg D.R. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J. Gen. Intern. Med. 2004, 19:357-365.
17. Hallinan R., Byrne A., Agho K., Dore G.J. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend. 2007, 88:49-53.
18. Hofer H., Watkins-Riedel T., Janata O., Penner E., Holzmann H., Steindl-Munda P., Gangl A., Ferenci P. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003, 37:60-64.
19. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G., Dietrich M., Trautwein C., Manns M.P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001, 345:1452-1457.
20. Jauncey M., Micallef J.M., Gilmour S., Amin J., White P.A., Rawlinson W., Kaldor J.M., van Beek I., Dore G.J. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J. Infect. Dis. 2004, 190:1270-1274.
21. Jowett S.L., Agarwal K., Smith B.C., Craig W., Hewett M., Bassendine D.R., Gilvarry E., Burt A.D., Bassendine M.F. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001, 94:153-158.
22. Kamal S.M., Moustafa K.N., Chen J., Fehr J., Abdel Moneim A., Khalifa K.E., El Gohary L.A., Ramy A.H., Madwar M.A., Rasenack J., Afdhal N.H. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006, 43:923-931.
23. Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., Strathdee S.A., Thomas D.L. Limited uptake of hepatitis C treatment among injection drug users. J. Community Health 2008, 33:126-133.
24. Mehta S.H., Lucas G.M., Mirel L.B., Torbenson M., Higgins Y., Moore R.D., Thomas D.L., Sulkowski M.S. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. Aids 2006, 20:2361-2369.
25. Morrill J.A., Shrestha M., Grant R.W. Barriers to the treatment of hepatitis C, patient, provider, and system factors. J. Gen. Intern. Med. 2005, 20:754-758.
26. NCHECR, 2008. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2008. National Centre in HIV Epidemiology and Clinical Research, Sydney.
27. Razali K., Thein H.H., Bell J., Cooper-Stanbury M., Dolan K., Dore G., George J., Kaldor J., Karvelas M., Li J., Maher L., McGregor S., Hellard M., Poeder F., Quaine J., Stewart K., Tyrrell H., Weltman M., Westcott O., Wodak A., Law M. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007, 91:228-235.
28. Restrepo A., Johnson T.C., Widjaja D., Yarmus L., Meyer K., Clain D.J., Bodenheimer H.C., Min A.D. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J. Viral Hepat. 2005, 12:86-90.
29. Rocca L.G., Yawn B.P., Wollan P., Kim W.R. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann. Fam. Med. 2004, 2:116-124.
30. Santantonio T., Fasano M., Sinisi E., Guastadisegni A., Casalino C., Mazzola M., Francavilla R., Pastore G. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 2005, 42:329-333.
31. Seal K.H., Currie S.L., Shen H., Anand B.S., Bini E.J., Brau N., Jeffers L., Wright T.L. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?. J. Clin. Gastroenterol. 2007, 41:199-205.
32. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33. (quiz 34-57).
33. Stein M.D., Maksad J., Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001, 61:211-215.
34. Stoove M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 2005, 77:81-86.
35. Strathdee S.A., Latka M., Campbell J., O'Driscoll P.T., Golub E.T., Kapadia F., Pollini R.A., Garfein R.S., Thomas D.L., Hagan H. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin. Infect. Dis. 2005, 40(Suppl 5):S304-S312.
36. Walley A.Y., White M.C., Kushel M.B., Song Y.S., Tulsky J.P. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J. Subst. Abuse Treat. 2005, 28:181-187.
37. Walsh N., Lim M., Hellard M. Using a surveillance system to identify and treat newly acquired hepatitis C infection. J. Gastroenterol. Hepatol. 2008, 23:1891-1894.
38. Wiegand J., Buggisch P., Boecher W., Zeuzem S., Gelbmann C.M., Berg T., Kauffmann W., Kallinowski B., Cornberg M., Jaeckel E., Wedemeyer H., Manns M.P. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43:250-256.